Globus Medical, Inc.
GMED
NYSE·Healthcare·Medical - Devices·Mkt cap $10.9B
$80.66
▲ +0.22%
P/E
20.32
Mkt Cap
$10.9B
52-Wk Range
$54.15–$101.40
52-Week Range
$54.15 - $101.40
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 37.2% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Comprehensive product portfolio spanning multiple musculoskeletal specialties
- Strong research and development capabilities driving innovation in implant technology
- Established distribution networks and international market presence
- Regenerative biologic products offering differentiation in treatment options
Bear Case
1 risk
- Average volatility.
Growth
Stable outlook
Aging global population increasing demand for spine and joint replacement surgeries
Value
Attractively priced below Medical Devices peer average
Momentum
Stable
+3.5% over 3m
Quality
Excellent
Excellent business quality
Dividend
None
No dividend
Smart-money signal
Who's buying GMED right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 5, 2026
AUG 6, 2026
Reported EPS of $1.34 vs $1.10 consensus (+21.8% surprise). Revenue of $789.6M vs $782.9M expected (+0.9%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+21.8%
Revenue trend · last 8Q
—
—
-1%
+18%
+23%
+26%
+27%
+6%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$625.7M
$657.3M
$598.1M
$745.3M
$769.0M
$826.4M
$759.9M
$789.6M
Margins · last 8Q
Gross
0.0%
Operating
23.1%
Profit
19.2%
Wall Street consensus
5 analysts · 80% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
80%
Hold
20%
Sell
0%
Median Price Target
—
Latest: UBS · Jul 28, 2026
vs Industry
How GMED stacks vs Medical - Devices
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related